Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|August 27, 2016
[Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations]Qunhui Wang, Hua Zheng, Fanbin Hu, et al.
BMC Medicine|September 10, 2024
Integration of clinical and blood parameters in risk prognostication for patients receiving immunochemotherapy for extensive stage small cell lung cancer: real-world data from two centersXiaomi Li, Li Tong, Shan Wang, et al.
Respiratory Research|December 31, 2018
Investigating the mechanism by which SMAD3 induces PAX6 transcription to promote the development of non-small cell lung cancerZhe Qian, Qiankun Zhang, Ying Hu, et al.
BMC Cancer|October 12, 2023
Plasma hepatocyte growth factor as a noninvasive biomarker in small cell lung cancerCong Zhao, Li Tong, Bin Liu, et al.
Cell Biochemistry and Biophysics|June 5, 2016
High levels of Phosphatase and Tensin Homolog Expression Predict Favorable Prognosis in Patients with Non-small Cell Lung CancerXuebing Li, Yuan Yang, Haiqing Zhang, et al.
British Journal of Cancer|February 14, 2018
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)Baohui Han, Kai Li, Yizhuo Zhao, et al.
Molecular Oncology|August 29, 2021
Role of aneuploid circulating tumor cells and CD31+ circulating tumor endothelial cells in predicting and monitoring anti-angiogenic therapy efficacy in advanced NSCLCTongmei Zhang, Lina Zhang, Yuan Gao, et al.
Cancer Letters|August 8, 2023
Longitudinal detection of subcategorized CD44v6+ CTCs and circulating tumor endothelial cells (CTECs) enables novel clinical stratification and improves prognostic prediction of small cell lung cancer: A prospective, multi-center studyYing Wang, Lina Zhang, Jinjing Tan, et al.
Cancer Medicine|February 18, 2020
Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trialYing Cheng, Baohui Han, Kai Li, et al.
The Lancet. Respiratory Medicine|June 23, 2025
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trialYuankai Shi, Lin Wu, Yinghua Ji, et al.
Pageof 8